US stock futures fall ahead of key PCE inflation data
David R. Epstein, a director at Tempus AI, Inc. (NASDAQ:TEM), recently sold 620 shares of the company's Class A Common Stock. The timing of this sale comes as the stock has experienced an 18.7% decline over the past week, according to InvestingPro data. The shares were sold at an average price of $41.81 each, totaling approximately $25,922. Following this transaction, Epstein holds 27,894 shares directly. This sale was executed under a Rule 10b5-1 trading plan, which was adopted on August 27, 2024. InvestingPro data shows analyst targets ranging from $50 to $74, with 2 analysts recently revising earnings estimates upward. Get access to more exclusive insider trading patterns and 6 additional ProTips with an InvestingPro subscription.
In other recent news, Tempus AI has been the focus of several key developments. The company's recent earnings report has led to a significant adjustment in its stock price target by Piper Sandler, increasing it from $40 to $70. Despite this positive adjustment, Piper Sandler maintains a neutral rating on the shares, indicating a cautious outlook on the company's future prospects.
Stifel, on the other hand, has downgraded Tempus AI stock from Buy to Hold, but increased the price target to $65. Needham has also raised its stock price target for Tempus AI to $56, maintaining its Buy rating.
In terms of acquisitions, Tempus AI's recent purchase of Ambry Genetics is seen as a strategic move that promises significant opportunities in data and applications over time. The company has also partnered with Avacta Therapeutics to utilize AI in advancing oncology drug development.
Additionally, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, has recently received FDA clearance. These are the recent developments surrounding Tempus AI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.